Neuphoria Therapeutics Inc (NEUP) AI Stock Analysis

Neuphoria Therapeutics Inc., formerly known as Bionomics Limited, is a clinical stage biopharmaceutical company based in Millis, Massachusetts. Incorporated in 1996, the company develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators under a research collaboration and license agreement with Merck & Co., Inc. targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions.

Financial results have experienced high volatility across recent periods. Revenue dropped 99.6% in FY2020 to $32,062 before increasing 2793.0% to $927,544 in FY2021. In FY2022, revenue declined 58.7% to $383,156 with an operating margin of -8095.2%. Revenue climbed 3984.4% in FY2025 to reach $15.6M with a gross margin of 95.8% and net income of -$369,632. However, FY2026 revenue fell 92.5% to $1.2M. For FY2026, the company recorded a gross margin of 43.5%, an operating margin of -835.5%, and a net loss of -$13.5M, yielding an EPS of -$4.22. For the trailing twelve months ended June 30, 2026, operating margin was -15.7% and EPS was -$3.06.

As of June 30, 2026, Neuphoria Therapeutics reported cash and short-term investments of $19.9M and total debt of $34,345, leaving net cash of $19.8M. Total assets stood at $28.7M against shareholders' equity of $24.6M, with a debt-to-equity ratio of 0.00 and a current ratio of 27.85. In FY2026, capital expenditures were $4, while operating cash flow and free cash flow both stood at -$12.35B. Over a five-year period, the company's share count change was -99.5%.

Neuphoria Therapeutics has a market capitalization of $17.9M and an enterprise value of $82,523. Its price-to-sales ratio of 15.2x sits above the 4.1x median of its US-listed Healthcare peers, while its price-to-book ratio is 0.8x and its EV to revenue is 0.1x. Over the past 52 weeks, NEUP shares experienced a return of -78.2%, underperforming the SPDR S&P 500 ETF Trust (SPY) return of 16.8%. The stock has returned -14.9% year-to-date and closed at $3.30 on October 16, 2026, which is 21.4% below its 200-day average.

Wall Street analyst coverage consists of 1 Hold rating with 0 Buy and 0 Sell ratings. The mean price target is $7.00, representing a potential upside of 112.1% from the last close of $3.30. For the current fiscal year ending June 30, 2027, the consensus EPS estimate is -$2.43 on expected revenue of $0. For the following fiscal year, 1 analyst estimates an EPS of -$2.46 on revenue of $0. The company achieved 3 EPS beats over the last 4 quarters, and its next earnings date is November 13, 2026.

This page is an AI-written research summary of Neuphoria Therapeutics Inc (NEUP). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NEUP income statement, NEUP balance sheet, NEUP key metrics, NEUP analyst forecast, NEUP chart. See the NEUP stock overview for the latest quote and news.